Core Viewpoint - The report highlights the financial performance and operational developments of Shanghai Rendu Biotechnology Co., Ltd. for the first half of 2025, indicating a decrease in revenue and profit due to various market factors while emphasizing the company's focus on RNA molecular diagnostics and innovation in technology platforms [1][3][12]. Company Overview - Shanghai Rendu Biotechnology Co., Ltd. is a leading enterprise in the field of RNA isothermal amplification technology and products, focusing on molecular diagnostics [3][6]. - The company operates in the medical device manufacturing industry, specifically in the production of in vitro diagnostic products [5][6]. Financial Performance - The company reported a revenue of approximately 81.24 million yuan for the first half of 2025, a decrease of 6.27% compared to the same period last year [3]. - The total profit for the period was approximately 764,383 yuan, reflecting a significant decline of 79.97% year-on-year [3]. - The net profit attributable to shareholders was approximately 2.04 million yuan, down 52.94% from the previous year [3]. Business Segments - The main business segments include molecular diagnostic reagents, instrument equipment, and third-party testing services [4][6]. - The company has developed a range of diagnostic products for reproductive, respiratory, digestive, and blood-borne diseases, with nearly 20 products recognized by major hospitals and laboratories [4][6]. Technological Innovation - The company has a patented technology platform for RNA real-time fluorescence isothermal amplification (SAT), which is crucial for its diagnostic products [2][16]. - A new technology platform, "Digital SAT + DigiNAT," has been developed, offering significant advantages over traditional methods, including simplified sample processing and faster detection [12][18]. Market Position - The company has established a strong market presence in the field of RNA molecular diagnostics, particularly in the detection of infectious diseases, with a focus on blood-borne pathogens [7][9]. - The RNA molecular diagnostics market in China is rapidly growing, with the company positioned to capitalize on this trend due to its innovative products and technologies [7][8]. Regulatory Compliance - The company has successfully obtained medical device registration for several new products, enhancing its product portfolio in the blood-borne pathogen detection field [13][20]. - The company adheres to national standards and regulations, ensuring compliance in its operations and product offerings [11][12]. Strategic Focus - The company is committed to continuous innovation and market expansion, with a focus on developing new products and enhancing its technological capabilities [12][14]. - Efforts are being made to strengthen partnerships with key clients and expand into international markets, including recent agreements with clients in the United States, Japan, and other countries [14][18].

Company Overview - Shanghai Rendu Biotechnology Co., Ltd. is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board with the stock code 688193 [2] - The company reported total assets of approximately 984.94 million yuan at the end of the reporting period, a decrease of 0.95% compared to the previous year [2] - The net assets attributable to shareholders of the listed company were not specified in the provided data [2] Financial Performance - The company's operating revenue for the reporting period was approximately 81.24 million yuan, reflecting a decline of 6.27% compared to the same period last year [2] - The total profit for the period was approximately 764.38 thousand yuan, a significant decrease of 79.97% year-on-year [2] - The net profit attributable to shareholders of the listed company was reported as -4.28 million yuan, indicating a substantial loss compared to a profit of -143.37 thousand yuan in the previous year [2] - The net cash flow from operating activities was -1.04 million yuan, a decrease of 109.96% compared to the previous year [2] Shareholder Information - As of the reporting period, the total number of shareholders was 3,495 [3] - The largest shareholder, residing overseas, holds 19.65% of the shares, amounting to 7.86 million shares [3] - The second-largest shareholder, also overseas, holds 15.44% of the shares, totaling 6.18 million shares [3] Important Events - The report indicates that there were no significant changes in the company's operating conditions during the reporting period [5]

Core Viewpoint - The company has actively implemented its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on R&D and innovation to enhance core competitiveness and investor returns [1][2][3]. Group 1: R&D and Innovation - The company is one of the earliest domestic enterprises specializing in RNA isothermal amplification technology, aiming to develop innovative diagnostic technologies and products to meet unmet clinical needs [1]. - The company has successfully developed a new technology platform "Digital SAT + Fully Automatic Supporting Equipment DigiNAT," which shows significant advantages over digital PCR technology, including simplified sample processing and faster detection speed [2][3]. - The company has initiated the development of RNA digital quantitative detection products, focusing on tumor screening and diagnosis, with progress in products for prostate cancer and bladder cancer [3]. Group 2: Market Development and Marketing Capability - The company has expanded its marketing network, developing 91 new terminal customers and adding 206 new products to hospitals, resulting in over 50% year-on-year revenue growth for certain blood-related products [4][5]. - The company has strengthened its academic promotion system, enhancing brand recognition and professional influence in core product lines [5]. Group 3: Internal Control and Cost Management - The company emphasizes cost control and efficiency enhancement, optimizing procurement management and improving resource utilization to lower operational costs [6]. - The company is actively monitoring industry policies and regulations to enhance internal control systems and ensure effective execution [6]. Group 4: Corporate Governance - The company is committed to improving its corporate governance structure and compliance awareness among key stakeholders, including major shareholders and executives [6][7]. - The company organizes training for its board members to enhance their understanding of securities market regulations and compliance [7]. Group 5: Investor Relations and Shareholder Returns - The company prioritizes investor relations management, ensuring accurate and timely information disclosure to maintain a positive market image [7]. - The company has established a reasonable profit distribution plan to reward investors, having completed the distribution of cash dividends for 2024 [7].

Fundraising Overview - The company raised a total of RMB 726.5 million by issuing 10 million shares at RMB 72.65 each, with a net amount of RMB 652.76 million after deducting issuance costs of RMB 73.74 million [1][2] - As of the report date, all raised funds have been received and verified by an accounting firm [2] Fund Utilization and Balance - Cumulative usage of the raised funds reached RMB 283.99 million, with RMB 31.16 million used in the first half of 2025 [2][6] - The company has RMB 380 million temporarily idle for cash management, with a remaining balance of RMB 18.24 million in the fundraising account [2][6] Fund Management System - The company established a fundraising management system to ensure the safety and efficiency of fund usage, complying with relevant laws and regulations [2][3] - A tripartite supervision agreement was signed with a bank and a sponsor to ensure strict approval for fund usage [3] Cash Management of Idle Funds - The company approved the use of up to RMB 430 million of temporarily idle funds for cash management, investing in safe and liquid financial products [4][5] - The report details various structured deposits and their expected returns, indicating a focus on capital preservation [5][6] Compliance and Reporting - The company has adhered to disclosure requirements, ensuring timely and accurate reporting of fundraising and usage status, with no violations noted [6][7]

上海仁度生物科技股份有限公司 关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 17 日（星期三）15:00-17:00 会议召开地点：上海证券交易所上证路演中心（https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 9 月 10 日（星期三）至 9 月 16 日（星期二）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@rdbio.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：688193 证券简称：仁度生物 公告编号：2025-039 上海仁度生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 ...

一、获证产品的基本信息 注：上述 CE 认证基于欧盟医疗器械法规（REGULATION (EU) 2017/746，简称 IVDR） 二、对公司的影响 新的欧盟体外诊断医疗器械法规（IVDR，EU2017/746）系替代原欧盟体外 诊断医疗器械指令（IVDD，98/79/EC）对欧盟市场的体外诊断医疗器械进行管 理。 本次 IVDR CE 证书的获得，标志着公司相关产品已经具备进入欧盟市场的 必要条件，有利于进一步提升公司体外诊断产品在欧盟市场的综合竞争力，将对 公司未来经营产生积极影响。 证券代码：688193 证券简称：仁度生物 公告编号：2025-038 上海仁度生物科技股份有限公司 关于公司产品获得 IVDR CE 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海仁度生物科技股份有限公司（以下简称"公司"）3 项核酸检测 试剂产品获得了由欧盟公告机构 TÜV 南德意志集团签发的 IVDR CE 证书。具体 获证情况如下： | 序号 | 产品名称 | 分类 | 注册证有效 期 | 证书编号 | ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-035 上海仁度生物科技股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》以及《上海证券交易 所上市公司自律监管指南第 1 号——公告格式》的相关规定，上海仁度生物科技 股份有限公司（以下简称"公司"、"本公司"）就 2025 年半年度（或"报告 期"）募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 经中国证券监督管理委员会作出《关于同意上海仁度生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]332 号文），并经上海证券交 易所同意，公司于 2022 年 3 月向社会公开发行人民币普通股 10,000,000 股，每 股面值人民币 1.00 元，溢价发行，每股发行价为人民币 72.65 元，募集资金总额 为人民币 726,500,00 ...

上海仁度生物科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年度评估报告 上海仁度生物科技股份有限公司（以下简称"公司"、"仁度生物"）于 2025 年 4 月 30 日发布了《2025 年度"提质增效重回报"行动方案》，自方案发布以 来，公司根据行动方案内容，积极开展、落实各项工作，进一步提高了公司经营 水平以及投资者回报。 为维护公司全体股东利益，践行"以投资者为本"的上市公司发展理念，公 司对 2025 年度"提质增效重回报"行动方案的执行情况进行了评估，现将该行 动方案半年度进展评估情况报告如下: 一、聚焦研发，着力创新，提升核心竞争力 公司是国内最早一批专注于 RNA 恒温扩增技术和产品的生命科学企业之一， 致力于开发临床需求尚未满足的创新诊断技术和产品。 公司紧抓当前社会节奏加快、分级诊疗体系不断推进、检测范围扩大、诊断 精准化、筛查基层化、早诊早治趋势凸显等行业发展趋势，扎根 RNA 分子诊断 领域，以生殖道、呼吸道病原体检测和血液传染病检测等为切入点，通过差异化 的产品策略，布局感染领域、肿瘤检测、伴随诊断等领域的产品研发，以临床价 值高、市场应用广泛以及更精准、高效的诊断 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-037 上海仁度生物科技股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 金用途和损害公司及全体股东利益的情况，不存在募集资金存放和使用违规的 情形。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届监事会第十一 次会议于 2025 年 8 月 28 日在公司二楼会议室以现场结合通讯的表决方式召开。 会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。公司董事、 高级管理人员列席了监事会会议。本次监事会会议的召集、召开程序符合公司 章程和有关法律、法规的要求。经与会监事审议和表决，会议形成决议如下： 一、 审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 经核查，监事会认为：报告期内，公司的财务核算体制健全，会计事项的 处理、财务报表的编制及公司执行的会计制度符合有关法律法规的要求，所包 含的信息能从各个方面真实地反映出公司当期的经营管理和财务状况等事项， 财务报告中的数据 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-036 上海仁度生物科技股份有限公司 关于第二届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会第十三 次会议于 2025 年 8 月 28 日以现场结合通讯的表决方式在公司会议室召开，会议 应到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。公司监事、高 级管理人员列席了董事会会议。本次董事会会议的召集、召开程序符合公司章程 和有关法律、法规的要求。经与会董事审议和表决，会议形成决议如下： 一、 审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 本议案无需提交股东大会审议。 具 体 内 容 详 见 本 公 司 2025 年 8 月 30 日 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《2025 年半年度报告》、《2025 年半年度报告摘要》。 二、 审议通过《关于公司<2025 年半年度募集资金存放与实际使 ...